Oncology Briefings™: Nursing Approaches to Managing Patients With Castrate-Resistant Prostate Cancer in an Era of Evolving Sequencing Considerations

 

Release Date: August 28, 2020
Expiration Date: August 28, 2021

Activity Overview

This online activity is designed to provide a concise and focused overview on an important clinical topic and includes information on the complex disease pathophysiology and etiology of prostate cancer, with focus on castrate-resistant prostate cancer (CRPC) in both the non-metastatic and metastatic settings. The activity will discuss the efficacy and safety profiles of therapies recommended for management as well as best practices for providing tam-based, multidisciplinary care and patient education and support. The engaging, multimedia format of this activity includes audio commentary from expert thought leaders integrated with text-based elements.
 

Acknowledgement of Commercial Support

This activity is supported by educational grants from AstraZeneca, Merck & Co., Inc., and Sanof Genzyme.
 

Target Audience

This activity is directed toward oncology and urology nurses who manage patients with castrate-resistant prostate cancer (CRPC). Other oncology healthcare professionals (HCPs) involved in the management of patients with CRPC are invited to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:
 

• Describe the mechanistic activity and the safety and efficacy profiles for therapies used to treat prostate cancer
• Summarize evidence for selecting and sequencing therapies for patients with prostate cancer
• Implement personalized treatment plans for patients with both early and advanced prostate cancer
• Evaluate emerging data from key clinical trials investigating novel agents for prostate cancer

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME guidelines, PER^® has identified and resolved all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Faculty

Disclosures: Consultant: Astellas Pharma, AstraZeneca, Bayer, Foundry Pharma, Janssen Pharmaceutica, Sanofi, Sema4, TeneoBio
 

Disclosures: Lindsay Diamond, NP, MSN, OCN, has no relevant financial relationships with commercial interests.

The staff of Physicians’ Education Resource^®, LLC (PER^®), have no relevant financial relationships with commercial interests to disclose.
 

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant as a substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.